Work

EMA - Alofisel withdrawn from the EU market

Year: 2025

Type: other

Abstract: Data from a recent study have shown that Alofisel, a medicine used to treat complex anal fistulas (abnormal passages between the lower parts of the gut and the skin near the anus) in adults with Crohn’s disease, does not work well enough. The available data indicate that the benefit of Alofisel is no longer demonstrated and therefore it would not outweigh the risks associated with its use. More information on the EMA Website.

Source: Industrias Culturais (Universidade de Coimbra)

DOI: 10.58079/138p7

Author: Vroby

Language: English

Topic: Inflammatory Bowel Disease

Subfield: Genetics

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: green

OpenAlex ID: W6936680631

Cites:

Cited by:

Related to: